The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCINE.L Regulatory News (CINE)

  • There is currently no data for CINE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Results of Rump Placing

20 Feb 2018 14:39

RNS Number : 4271F
Cineworld Group plc
20 February 2018
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, HONG KONG OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND NOT A PROSPECTUS AND THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM PART OF, AND SHOULD NOT BE CONSTRUED AS, ANY OFFER, INVITATION OR RECOMMENDATION TO PURCHASE, SELL OR SUBSCRIBE FOR ANY SECURITIES IN ANY JURISDICTION AND NEITHER THE ISSUE OF THE INFORMATION NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF OR BE RELIED UPON IN CONNECTION WITH, OR ACT AS AN INDUCEMENT TO ENTER INTO, ANY INVESTMENT ACTIVITY. ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL OR OTHERWISE DISPOSE OF ANY SECURITIES MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS

PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

FOR IMMEDIATE RELEASE

20 February 2018

CINEWORLD GROUP PLC

RESULTS OF RUMP PLACING

Following the announcement earlier today regarding valid acceptances under the fully underwritten Rights Issue announced by Cineworld Group plc ("Cineworld" or the "Company") on 17 January 2018, the Company confirms that Barclays Bank PLC, HSBC Bank plc and Investec Bank plc have procured subscribers for all of the 40,383,167 New Ordinary Shares for which valid acceptances were not received, representing approximately 3.69 per cent. of the total number of New Ordinary Shares, at a price of 238 pence per New Ordinary Share.

The net proceeds from the placing of such New Ordinary Shares (after the deduction of the Rights Issue Price of 157 pence per New Ordinary Share and the expenses of procuring subscribers including any applicable brokerage and commissions and amounts in respect of VAT which are not recoverable, if any) will be paid (without interest) to those persons whose rights have lapsed in accordance with the terms of the Rights Issue, pro rata to their lapsed provisional allotments, save that individual amounts of less than £5.00 will not be paid to such persons but will be paid to the Company.

Following the allotment of the New Ordinary Shares to reflect the shares for which Barclays Bank PLC, HSBC Bank plc and Investec Bank plc have procured subscribers, the Company's issued share capital will consist of 1,369,631,475 ordinary shares of one pence each. The Company holds no ordinary shares in treasury. Therefore, as at 20 February 2018, the total number of voting rights in the Company is 1,369,631,475. This figure may be used by Shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change in their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

As announced earlier today, the Company currently expects Completion to occur after market hours (London time) on 28 February 2018 and that Re-admission will occur at 8.00am on 1 March 2018.

Capitalised terms used in this announcement have the meanings given to them in the combined prospectus and class 1 circular dated 17 January 2018 (the "Prospectus"), which is available on the Company's website (www.cineworldplc.com) and may be inspected at the registered office of the Company at 8th Floor, Vantage London, Great West Road, Brentford TW8 9AG during normal business hours on any Business Day up to and including the date of Re-admission.

For further details please contact:

Cineworld Group plc

+44 (0)20 8987 5000

Israel Greidinger

 

Nisan Cohen

 

 

 

 

 

 

 

Barclays (Joint Financial Adviser, Joint Underwriter, Joint Global Coordinator and Joint Corporate Broker to Cineworld)

+44 (0)20 7623 2323

Makram Azar

 

Daniel Ross

 

Mark Astaire

 

James Colburn

 

 

 

 

 

HSBC (Joint Financial Adviser, Joint Underwriter and Joint Global Coordinator to Cineworld)

+44 (0)20 7991 8888

Philip Noblet

 

Noam Kleinfeld

 

James Thomlinson

 

Mark Dickenson

 

Sam Barnett

 

 

 

Investec Bank plc (Sponsor, Joint Underwriter, Joint Bookrunner and Joint Corporate Broker to Cineworld)

+44 (0)20 7597 4000

 

 

Chris Sim

 

George Price

 

Jonathan Wynn

 

Robert Baker

 

 

 

 

 

Powerscourt (Public Relations Adviser to Cineworld)

+44 (0)20 7250 1446

 

 

Nick Dibden

 

Rob Greening

 

Lisa Kavanagh

 

IMPORTANT NOTICE

The contents of this announcement have been prepared by and are the sole responsibility of Cineworld.

This announcement is not a prospectus but an advertisement and investors should not acquire any securities referred to in this announcement except on the basis of the information contained in the Prospectus. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed by any person for any purpose on the information contained in this announcement or its accuracy, fairness or completeness.

Neither the content of Cineworld's website nor any website accessible by hyperlinks on Cineworld's website is incorporated in, or forms part of, this announcement.

This announcement is not for publication or distribution, directly or indirectly, in or into the United States. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy, securities to any person in the United States, Australia, Canada, Japan, Hong Kong or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to herein may not be offered or sold in the United States unless registered under the US Securities Act of 1933, as amended (the "Securities Act") or offered in a transaction exempt from, or not subject to, the registration requirements of the Securities Act. The offer and sale of securities referred to herein has not been and will not be registered under the Securities Act or under the applicable securities laws of Australia, Canada, Japan or Hong Kong. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or Hong Kong or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or Hong Kong. There will be no public offer of the securities in the United States, Australia, Canada, Japan or Hong Kong.

This announcement does not constitute a recommendation concerning participation in the Rights Issue. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. The contents of this announcement are not to be construed as legal, business, financial or tax advice. Each shareholder or prospective investor should consult his, her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.

Each of Barclays Bank PLC, acting through its Investment Bank ("Barclays"), HSBC Bank plc ("HSBC") and Investec Bank plc ("Investec" and together with Barclays and HSBC, the "Underwriters") is authorised by the Prudential Regulation Authority and regulated in the United Kingdom by the Financial Conduct Authority and the Prudential Regulation Authority. Each of the Underwriters is acting exclusively for Cineworld and no one else in connection with the Transaction or any other matter referred to in this announcement and will not be responsible to anyone other than Cineworld for providing the protections afforded to their respective clients nor for providing advice in relation to the Transaction or any other matter referred to in this announcement. Neither the Underwriters nor any of their respective subsidiaries, branches or affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of the Underwriters in connection with this announcement, any statements contained herein or otherwise.

Information to Distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares have been subject to a product approval process, which has determined that they each are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares may decline and investors could lose all or part of their investment; the Nil Paid Rights, the Fully Paid Rights and the New Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Underwriters will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Nil Paid Rights, the Fully Paid Rights and/or the New Ordinary Shares and determining appropriate distribution channels.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROIFKKDNQBKDPBB
Date   Source Headline
2nd Jan 201910:47 amRNSTotal Voting Rights
24th Dec 201811:22 amRNSTR-1: Standard Form of Notification
21st Dec 201810:57 amRNSTR-1: Standard Form of Notification
7th Dec 20182:38 pmRNSDirector/PDMR Shareholding
4th Dec 201811:32 amRNSTR-1: Standard Form of Notification
4th Dec 201811:25 amRNSTR-1: Standard Form of Notification
3rd Dec 20181:24 pmRNSTotal Voting Rights
29th Nov 20184:12 pmRNSTR-1: Standard Form of Notification
28th Nov 201812:09 pmRNSTR-1: Standard Form of Notification
27th Nov 20184:04 pmRNSTR-1: Standard Form of Notification
15th Nov 20187:00 amRNSTrading Update
9th Nov 20184:09 pmRNSBlock Listing Six Monthly Return
5th Nov 201811:10 amRNSTR-1: Standard Form of Notification
1st Nov 201811:45 amRNSTotal Voting Rights
1st Oct 201810:52 amRNSTotal Voting Rights
21st Sep 20185:08 pmRNSInterim Dividend - Exchange Rate
3rd Sep 20181:21 pmRNSTotal Voting Rights
15th Aug 20184:15 pmRNSTR-1: Standard Form of Notification
9th Aug 20187:00 amRNSHalf-year Report
6th Aug 20181:15 pmRNSTR-1: Standard Form of Notification
1st Aug 20183:42 pmRNSTotal Voting Rights
20th Jul 201810:35 amRNSDirectorate Change
10th Jul 201811:53 amRNSTR-1: Standard Form of Notification
5th Jul 201812:07 pmRNSDirector Declaration
2nd Jul 201810:51 amRNSTotal Voting Rights
29th Jun 20184:26 pmRNSTR-1: Standard Form of Notification
26th Jun 20183:25 pmRNSTR-1: Standard Form of Notification
26th Jun 20183:12 pmRNSDirector/PDMR Shareholding
14th Jun 20183:11 pmRNSTR-1: Standard Form of Notification
12th Jun 201811:25 amRNSTR-1: Standard Form of Notification
11th Jun 201810:34 amRNSTR-1: Standard Form of Notification
8th Jun 201811:29 amRNSTR-1: Standard Form of Notification
7th Jun 20184:19 pmRNSDirector Declaration
5th Jun 20182:42 pmRNSTR-1: Standard Form of Notification
1st Jun 201812:44 pmRNSTotal Voting Rights
23rd May 20189:51 amRNSAdditional Listing
16th May 20182:22 pmRNSResults of Annual General Meeting
16th May 20187:00 amRNSTrading Statement
14th May 20186:05 pmRNSDirector/PDMR Shareholding
11th May 20187:00 amRNSChange in Presentation Currency
8th May 201810:38 amRNSAdditional Listing
1st May 201811:21 amRNSTotal Voting Rights
24th Apr 20184:10 pmRNSDirector/PDMR Shareholding
17th Apr 20186:13 pmRNSTR-1: Standard Form of Notification
13th Apr 20185:28 pmRNSTR-1: Standard Form of Notification
11th Apr 20185:07 pmRNSAnnual Report and Notice of Annual General Meeting
19th Mar 20184:09 pmRNSPDMR/Director Shareholding
15th Mar 20187:00 amRNSPreliminary Results
1st Mar 20184:34 pmRNSTotal Voting Rights
1st Mar 20188:07 amRNSRe-admission of Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.